10x Genomics shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and a $60 price target.
Portfolio Pulse from Benzinga Newsdesk
10x Genomics' stock (TXG) is experiencing an uptick after Guggenheim initiated coverage with a Buy rating and set a price target of $60.

December 14, 2023 | 5:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
10x Genomics' shares are likely to see a positive short term impact following Guggenheim's Buy rating and $60 price target initiation.
Analyst ratings, especially from reputable firms like Guggenheim, can significantly influence investor sentiment and stock prices. The initiation of coverage with a Buy rating and a price target that suggests substantial upside from the current trading price is likely to lead to increased investor interest and a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100